Compare Cronos Group Inc (CRON) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Rocket Lab USA Inc — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.14B), while Rocket Lab USA Inc trades at $80.81 (market cap $50.01B). The key difference: Rocket Lab USA Inc is far larger — about 43.9× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals.
| CRON | RKLB | |
|---|---|---|
Market Cap | $1.14B | $50.01B |
Sector | Health | Technology |
52-Week High | $3.27 | $150.23 |
52-Week Low | $2.30 | $39.48 |
Enterprise Value | $341.13M | $47.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.165, up 5.5% with bullish technical signals from moving averages. The company shows strong revenue growth, with Q2 2026 beating expectations with $0.09 EPS versus $0.01 expected, and record quarterly performance. However, profitability remains inconsistent with negative net income in 2025. Analyst sentiment is mixed with 60% hold ratings, reflecting cautious optimism amid competitive pressures.
Outlook is cautiously optimistic with international expansion driving growth, but execution risks and cannabis sector volatility persist. The stock offers growth potential through European market penetration and product innovation, though investors should monitor margin improvements and competitive dynamics closely.
Rocket Lab (RKLB) trades at $81.17, up 1.41% today, showing strong momentum with a bullish technical outlook. The company reported record Q2 2026 revenue of $601.8M but missed EPS expectations, while maintaining a massive $2.36B backlog. Analysts remain overwhelmingly bullish with a $118 consensus target, though valuation metrics appear stretched with a P/S ratio of 60.8.
The stock offers significant upside potential driven by Neutron rocket development and growing space industry demand, but faces execution risks including margin pressures and cash burn. Near-term catalysts include the Neutron launch timeline and Iridium acquisition, though high valuation multiples require flawless execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
